Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
Keytruda plus chemotherapy reduced the risk of death by 27% in people with locally advanced or metastatic disease.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
Many older people have biomarkers indicative of a strong response to checkpoint inhibitors.
The immune system has a natural ability to shut down cells that grow out of control, but cancer has many ways to get around these defenses.
Keytruda after kidney cancer surgery prolonged disease-free survival rates in patients at high risk for recurrence.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
The immunotherapy is now approved to treat tumors with a specific genetic mutation anywhere in the body.
Researchers provide updates on the clinical trial of a new drug to improve the long-term survival of patients facing advanced melanoma
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.
Current and former smokers had better clinical outcomes with checkpoint inhibitors for lung cancer than nonsmokers.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.